1. Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer
- Author
-
D. M. Zahm, Jan Budczies, M K Mehta, E. Weiss, Manfred Dietel, S. Loibl, Ralf Kronenwett, Silvia Darb-Esfahani, Thomas Karn, M. Gehrmann, Hans Bojar, Carsten Denkert, F Khandan, Beyhan Ataseven, Achim Rody, Jan C. Brase, and G. von Minckwitz
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Receptor, ErbB-2 ,Breast Neoplasms ,triple negative ,predictive factor ,breast cancer ,Breast cancer ,Cell Line, Tumor ,Internal medicine ,Humans ,Medicine ,RNA, Messenger ,skin and connective tissue diseases ,Molecular Diagnostics ,Triple-negative breast cancer ,Reverse Transcriptase Polymerase Chain Reaction ,business.industry ,Gene Expression Profiling ,thymosin beta 15 ,Estrogen Receptor alpha ,Thymosin ,medicine.disease ,Clinical trial ,Logistic Models ,Clinical Trials, Phase III as Topic ,Immunology ,Female ,Thymosin beta 15a ,Receptors, Progesterone ,business ,Estrogen receptor alpha ,hormones, hormone substitutes, and hormone antagonists ,Chemotherapy response ,neoadjuvant chemotherapy - Abstract
Background: Biomarkers predictive of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) of breast cancer are urgently needed. Methods: Using a training/validation approach for detection of predictive biomarkers in HER2-negative breast cancer, pre-therapeutic core biopsies from four independent cohorts were investigated: Gene array data were analysed in fresh frozen samples of two cohorts (n=86 and n=55). Quantitative reverse transcription polymerase chain reaction (qRT–PCR) was performed in formalin-fixed, paraffin-embedded (FFPE) samples from two neoadjuvant phase III trials (GeparTrio, n=212, and GeparQuattro, n=383). Results: A strong predictive capacity of thymosin beta 15 (TMSB15A) gene expression was evident in both fresh frozen cohorts (P
- Published
- 2012
- Full Text
- View/download PDF